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ABSTRACT 
Monoclonal antibody and recombinant protein production benefits greatly from bovine serum 
as an additive.  The caveat is that bovine serum IgG, co-purifies with mAbs and IgG Fc-
containing fusion proteins and it presents a contaminant in the end products. In order to 
analytically validate the products, species specific reagents are needed that react with bovine 
IgG exclusively. Our attempts to find such commercially available reagents failed. Here, we 
report the production of species specific mAbs which recognize bovine IgG even in the 
presence of excess amount of mouse IgG. We present five mAbs: Bsi4028, Bsi4032, Bsi4033, 
Bsi4034 and Bsi4035 suitable to determine the presence of bovine IgG contamination via 
ELISA or immunoblotting in bioreactor derived mouse mAb preparations. To quantitate 
bovine IgG content we developed sensitive sandwich ELISAs capable to detect bovine IgG 
contaminant in the ng/ml (~10
-11
M/l) range. Finally, we show that bovine IgG is efficiently 
removed from bioreactor produced mouse mAb preparation via affinity depletion columns 
prepared with Bsi4028, Bsi4032, Bsi4033, Bsi4034, Bsi4035 mAbs.  
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1. INTRODUCTION 
Monoclonal antibodies are widely used reagents in life sciences. In the past decades, 
monoclonal antibody (mAb) production and application as research and diagnostic tools or as 
therapeutic agents for various human diseases has created a great deal of interest, which is 
constantly on the rise (Hagemeyer et al. 2009; Siddiqui 2010; Guergova-Kuras et al. 2011; 
Modjtahedi et al. 2012; Elvin et al. 2013). Apart from their recombinant forms which are 
generated in high producer CHO or other type of cells, most of the antibodies are produced 
using hybridomas, either in animals (in vivo) or in cell culture (in vitro) (Schirrmann et al. 
2008; Liu 2014). In vivo antibody manufacturing has been a widespread method of mAb 
production because of its reliability, high antibody yield and cost effectiveness (Jackson et al. 
1996; Peterson and Peavey 1998). However, because of ethical concerns and because 
antibodies have to meet strict quality control requirements (purity, similarity, identity) the 
number of animals used for antibody production for diagnostic and scientific purposes is 
continuously decreasing. In parallel, in recent years, numerous bioreactors have been 
developed for cultivation of hybridoma cells and several types of in vitro  antibody production 
methods were established (Nagel et al. 1999; Trebak et al. 1999; Ayyildiz-Tamis et al. 2014). 
Standard hybridoma cultures require bovine serum supplement for the effective and high 
yield, but also for the economically sound antibody production. Bovine serum supplemented 
media results in a considerable bovine protein contamination of mAb preparations. 
Rasmussen et al. reported that media defined as serum-free may contain up to 0.5 mg/L 
bovine IgG (Rasmussen et al. 2005). During the most widely used purification processes of 
mAbs (protein A or protein G), the contaminant bovine immunoglobulins co-purify with the 
specific mAbs of interest. Therefore, there is an apparent need to recognize and to reduce 
bovine immunoglobulin contamination of mAb preparations, additionally; monitoring mAb 
quality during production requires specificity, which enables detection of bovine IgG. Such 
requirements may be achieved by affinity reagents that react with bovine IgG exclusively. In a 
search for specific anti bovine antibodies (polyclonal or monoclonal) we found close to one 
hundred commercially available reagents, however, the majority of these were reported to 
react with mouse IgG as well. We also tried different vendors provided bovine IgG-specific 
antibodies of which the cross-reactive properties with murine IgG were not indicated, 
however, these antibodies also recognized murine IgG in addition to the bovine IgG. Thus, in 
order to fill in the need, we aimed to produce species specific mAbs that react with bovine 
IgG even in the presence of a huge excess of murine immunoglobulins. 
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2. MATERIALS AND METHODS 
2.1. Purity control of the monoclonal antibodies 
The purity control of mAbs produced was performed with a multi-step process involving 
SDS-PAGE, isoelectric focusing (IEF) and multi-Capillary Gel Electrophoresis (mCGE). For 
SDS-PAGE, purified mAbs (5 µg) and a protein standard (Thermo Fisher Scientific) were 
loaded on the 4-20% Tris-Glycine gel (Invitrogen), stained with Coomassie Brillant Blue and 
analyzed with densitometry (Carestream Gel Logic 2200 Pro imaging system) using 
Carestream MI SE software. For IEF, samples were separated on Novex pH 3-10 isoelectric 
focusing gel (Thermo Fisher Scientific) using Novex IEF Cathode Buffer pH 3-10 (Thermo 
Fisher Scientific) and Novex IEF Anode Buffer (Thermo Fisher Scientific) under conditions 
suggested by the manufacturer.  Isoelectric focusing standards (Serva) were also run and 
visualized by staining with Coomassie blue R-250. Multi-Capillary Gel Electrophoresis 
analysis was performed as described previously (Székely et al. 2014).  
 
2.2. Production of bovine IgG-specific mAbs 
Bovine IgG (Sigma, I5506) was used as antigen for the immunization of female 7-8-week old 
BALB/c mice as described earlier (Guergova-Kuras et al., 2011). Hybridoma supernatants 
were screened for the presence of anti-bovine IgG, via a direct ELISA, using immobilized 
bovine-IgG as antigen. Mouse IgG cross-reactivity was also screened with mouse IgG specific 
ELISA. Based on the ELISA results, hybridomas producing the highest specific anti-bovine 
IgG titers were cloned in 96 well plates via limiting dilution. Anti-bovine IgG producer mAbs 
were further characterized in direct, sandwich and competitive ELISA-s. Immunoglobulin 
isotype of bovine IgG specific mAbs was determined by isotype specific ELISAs using goat 
anti-mouse IgG UNLB (Southern Biotech) antibodies as capture reagents and biotin 
conjugated anti-mouse IgG1, IgG2a, IgG2b and IgG3 (Southern-Biotech) antibodies and 
streptavidin HRP (Invitrogen) for detection of the captured antibodies. Positive controls were 
purified unlabeled mouse IgG1, 2a, 2b and 3 also from Southern Biotech. 
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2.3. Antibody production 
2.3.1. In vivo production 
Some of the anti-bovine IgG specific mAbs (Bsi4028, Bsi4029, Bsi4030, Bsi4031, Bsi4032, 
Bsi4033, Bsi4034 and Bsi4035) and other antibodies used in the analysis (Bsi0271, Bsi0452, 
Bsi0097 and Bsi0358) were produced in vivo in BALB/c ascites. Briefly, ascites fluid was 
produced by intraperitoneal injection of 1–5 × 106 cloned hybridoma cells into ICFA-primed 
BALB/c mice. All animal study protocols were approved by the Animal Care and Protection 
Committee at the University of Debrecen (no. 7/2011/DE MAB).  
2.3.2. In vitro production 
Monoclonal antibodies used for the evaluation (Bsi0271, Bsi0452, Bsi0097 and Bsi0358) 
were produced in vitro using the CELLine™. Two-Compartment Bioreactor Technology (BD 
Biosciences). Briefly, monoclonal  hybridomas were seeded into the “cell” compartment, and 
were maintained in DMEM (PAA Laboratories) supplemented with 16% fetal calf serum 
(FCS Gold, PAA Laboratories), 2 mM L-glutamine (PAA Laboratories), and antibiotics (PAA 
Laboratories), while the nutrient compartment medium was identical with that of the cell 
compartment except it was serum-free.   
 
2.4 Antibody purification from ascites and from bioreactor preparations. 
Immunoglobulin was purified from ascites fluid, using a two-step affinity chromatography 
procedure consisting of a thiophilic adsorbent column (Thermo Fisher Scientific) and a 
Protein G-Sepharose 4 FF (GE Healthcare) column purifications followed by protein 
concentration measurement with the BCA protein assay kit (Thermo Fisher Scientific). 
Bovine and mouse IgG were purified from sera using this method as well. Purification of cell 
culture supernatants from BD CELLine System was achieved by the protein G method. 
 
2.5. Antibody labeling 
Purified mAbs were biotinylated with EZ-Link® Sulfo-NHS-Biotin (Thermo Fisher 
Scientific) following the manufacturer's instructions. Bound biotin quantitation was 
determined with the HABA method and calculated with the HABA calculator found 
conveniently on the Pierce Biotechnology web site 
(http://www.piercenet.com/haba/habacalcmp.cfm).  
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2.6. ELISA assays 
 
2.6.1. ELISA 1. : Screen ELISA 
The assay was performed as follows: flat-well, half-area ELISA plates, (Costar3690) were 
coated with 30 μl, 1 μg/ml of bovine IgG (Sigma) or 1 μg/ml of IgG from murine serum 
(Sigma) in carbonate coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6), hereinafter  
CCB, for 60 minutes, without shaking at 37 °C. Plates were washed 2 times with phosphate-
buffered saline containing 0.05% Tween (PBS-T). Remaining free binding sites were blocked 
with blocking buffer (PBS-B) containing 5 mg/ml polyvinylpyrrolidone (PVP, Sigma) in 
PBS-T for 30 minutes at 37 °C without shaking, then the plates were washed two times with 
PBS-T. Serum samples from the immunized BALB/c mice and hybridoma culture supernatant 
were diluted in PBS-B and incubated for 1 h at 37 °C without shaking. Plates were then 
washed three times with PBS-T and incubated for 30 minutes at 37 °C, without shaking, with 
HRP labelled goat anti-mouse IgG-HRP (Southern-Biotech) diluted to 1:5000 in PBS-B. 
After washing the plates four times with PBS-T, enzyme reaction was developed using 
(0.01%) hydrogen-peroxide (diluted from 30 % stock solution, VWR) as substrate and TMB 
as chromogen (0,1 mg/ml Sigma) at 37 °C, without shaking for 2-3 minutes. Reactions were 
stopped with 30 µl/well of 4N H2SO4. The progression of the colorimetric reactions were 
measured with reading at 450 nm using the Multiskan Ascent (Model number: 354) 
microplate reader (Thermo Fisher Scientific) at room temperature. Raw measurements were 
background (incubated with PBS-B instead of plasma samples) corrected. 
 
2.6.2. ELISA 2. : Sandwich ELISA detection of “bovine” IgG (polyclonal commercial Ab, 
Vendor#1)  
Assays were performed as described in 2.6.1, with the exception of the following details: For 
the quantification of bovine IgG, quantitative sandwich-ELISAs, using species specific anti-
IgG antibody pairs were carried out. Purified, unlabeled anti-bovine IgG antibodies were used 
as capture reagents, and the bound antigen (bovine IgG) was detected with anti-bovine IgG-
HRP conjugate. For the determination of bovine IgG levels, we used HRP labeled and 
unlabeled anti-bovine IgGs from different vendors. The assays were carried out as follows: 
ELISA plates were coated with 1 µg/ml of capture antibody (obtained from vendor 1 or 
vendor 2) for 60 minutes at 37
o
C, diluted in CCB. After incubation the plates were blocked 
using PBS-B, then incubated with in vitro and in vivo produced antibodies, bovine or mouse 
IgG from bovine and mouse sera. Captured antibodies were detected with the commercially 
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available HRP-conjugated polyclonal anti-bovine IgG-s. IgG from murine serum (Sigma) and 
bovine IgG (Sigma) were used as standards and controls. 
 
2.6.3. ELISA 3. : Sandwich ELISA detection of “mouse” IgG (polyclonal commercial Ab) 
Assays were developed as described in 2.6.1, with the exception of the following details: 
Plates were coated with 30 µl/well of 1 µg/ml goat anti-mouse IgG UNLB (Southern Biotech) 
at 37 °C for 60 minutes in CCB, without shaking. After washing the plates for 2 times with 
PBS-T wells were blocked at 37 °C for 30 minutes in 60 µl/well of PBS-B. Plates were 
washed then 3 times, and subsequently incubated with in vitro or in vivo produced antibodies, 
bovine or mouse IgG from bovine or mouse sera, at 37 °C for 60 minutes as antigens without 
shaking. Antigens were detected with HRP labelled goat anti-mouse IgG (Southern-Biotech) 
secondary antibodies diluted to 1:5000.  
2.6.4. ELISA 4. : Direct ELISA for characterization of anti-bovine mABs 
Measurements were done as described in 2.6.1, with the exception of the following details: 
Eight anti-bovine mAbs produced by hybridoma monoclones were first analyzed with direct 
ELISA using bovine IgG as immobilized antigen. Plates were coated with 1 μg/ml of bovine 
IgG (Sigma) in CCB for 60 minutes at 37 °C, without shaking. Non-specific binding was 
blocked with PBS-B. Biotinylated bovine IgG specific mAbs were diluted in PBS-B and 
incubated for 1 h at 37 °C without shaking and antigens were detected by streptavidin HRP 
(Invitrogen) diluted to 1:4000. 
 
2.6.5. ELISA 5. : A representative sandwich ELISA 
Tests were performed as described in 2.6.1, with the exception of the following details: Five 
mAbs showing higher relative affinity to bovine IgG were further characterized using a 
sandwich ELISA protocol as follows, ELISA plates were coated with 1 µg/ml of capture 
antibody (Bsi4028, Bsi4032, Bsi4033, Bsi4034, Bsi4035) diluted in CCB. Plates were washed 
then three times and incubated with the ten-fold dilution series (starting at 1 µg/ml) of bovine 
IgG (Sigma) at 37 °C for 60 minutes as antigen without shaking. Captured bovine IgG was 
detected with biotinylated mouse anti-bovine mAbs and streptavidin HRP (Invitrogen). All 
possible capture / detection mAb combinations were tested.  
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2.6.6. ELISA 6: Competitive Inhibition ELISA 
Assays were done as described in 2.6.1, with the exception of the following details: In order 
to determine the relative affinity of anti-bovine mAbs, all the studied mAbs were tested with 
competitive ELISA on immobilized antigen (bovine IgG). Briefly, the wells were coated with 
1 µg/ml bovine IgG, washed with PBS-T and blocked with PBS-B, then incubated with 
biotinylated mAbs in fixed concentration (1 µg/ml) pre-mixed with a dilution series of 
individual unlabeled competitor mAbs starting from 10 µg/ml and developed with 
streptavidin-HRP. All possible capture / inhibitor combinations were tested. 
2.6.7. ELISA 7: Sandwich ELISA detection of “bovine” IgG (BSI monoclonal Ab) in the 
presence of murine IgG 
ELISAs were performed as described in 2.6.1, with the exception of the following details: 
Plates were coated with 1 μg/ml of anti-bovine mAb (Bsi4028) CCB for 60 minutes at 37 °C 
temperature, then blocked with PBS-B, washed three times and incubated with in vitro and in 
vivo produced antibodies, including bovine or mouse IgG from sera or fixed, low amount of 
bovine IgG (10 ng/ml) in the presence of varying amounts of murine IgG. Incubation was 
carried out at 37 °C for 60 minutes without shaking. Biotinylated bovine IgG specific mAbs 
were diluted in PBS-B and incubated, finally binding was detected via streptavidin HRP 
(Invitrogen) diluted to 1:4000.  
 
2.6. Western Blot Analysis 
For immunoblot analysis, 1 µg of bovine IgG purified from sera, or 2 µg serum samples from 
different species (human, gorilla, simian, tiger, lion, dog, horse, camel, alpaca, pig, goat, 
sheep, rabbit, BALB/c mouse, SCID mouse, rat, crow, swan, eagle, turkey, chicken, painted 
turtle, Moorish tortoise) were loaded for SDS-PAGE onto 5–12% Tris-glycine gels. After 
separation the samples were transferred to a nitrocellulose membrane (Whatman). The 
membranes were blocked with 5 mg/ml PVP in PBST, and incubated either with goat anti-
mouse IgG HRP (Southern Biotech) or polyclonal anti-bovine IgG Peroxidase produced in 
rabbit (Vendor#1), or the Bsi4028 mAb conjugated to biotin first then with Streptavidin HRP 
(Invitrogen) for 1 hour. Immunoblots were developed by Pierce™ ECL Western Blotting 
Substrate (Thermo Fisher Scientific) according to the manufacturer’s guide and detected with 
the Gel Logic 2200 Pro Imaging System (Carestram).  
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2.7. Affinity removal of bovine IgG from artificial mixes and from bioreactor produced 
mouse mAb preparations 
2.7.1. Anti-bovine IgG affinity column preparation: we used 1.5 ml sepharose slurry of 
Protein G Sepharose 4 Fast Flow (GE Healthcare) (about 1 ml settled sepharose).  In total, 10 
mg of anti-bovine IgG specific mAbs (2-2-mg of each, Bsi4028, Bsi4032, Bsi4033, Bsi4034, 
Bsi4035) were added to the Protein G Sepharose, supplemented with cross linking agent DMP 
(Thermo Scientific)  in binding buffer (0.1M Na2PO4, 0.01% Tween-20, pH 8.2) in 10 ml 
final volume. Subsequently the sepharose slurry was washed once with 2 ml PBS, twice with 
2 ml 0.2 M Triethanolamine buffer (pH 8.35).   
 
2.7.2. Removal of bovine IgG from mixes of mouse mAb plus bovine IgG and from mouse 
mAb preparations.  
 
Anti-bovine affinity column was washed two times with 5 ml PBS, samples were added then 
in a 15 ml centrifuge tube, incubated overnight at 4˚C on a rotator (Stuart Tube Rotator SB3, 
Bibby Scientific). During the next day, the Sepharose slurry was loaded to a glass column 
equipped with a filter, and the flow through and wash 5× (1 ml PBS) samples were collected. 
Columns were re-used after elution of bound material with 0.1 M glycine-HCl (pH 2.7) 
elution buffer followed by washing with wash buffer. Mouse IgG and bovine IgG 
concentrations were detected by ELISA 3 and 7 respectively.  
 
 
2.8. Calculations, statistics. 
IC50 concentrations of the different monoclonal antibodies in the competitive inhibition assays 
were calculated using GraphPad Prizm software. Statistical analysis of the specific and 
background ELISA signals was performed with t-test with equal variances using Microsoft 
Excel.  
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3. RESULTS AND DISCUSSION 
3.1. Routine purity control procedures fail to detect non-clonal (bovine) IgG 
contamination in mAb prepations 
Purity controls of murine mAbs are performed routinely using either CGE and/or SDS-PAGE 
(Szekely et. al 2014). An example showed on figure 1 (panels A, B, D and E) indicates that 
the purity of the mAbs produced both in vivo and in vitro in our laboratories  is high, as 
determined either by CGE or SDS-PAGE. No detectable contamination was observed using 
these methods. However, analytical iso-electrofocusing reveals the presence of some non-
uniformity (Fig 1 panels C and F), most likely emerged from the altered processing of the IgG 
molecules which may include glycosylation variants (e.g. sialylation), deamidation or C-
terminal lysine processing variants, introducing negative (sialic acid) or positive (unprocessed 
lysine variant) charges to the molecules (He et al. 2009).  None of the deployed analytical 
procedures can detect however, the presence of non-clonal antibodies (i.e. bovine IgG) in the 
“production” culture fluid, which co-purifies with the product. We conclude that although the 
first results of the analytical checking of our antibodies seem to be favorable, we still do not 
know how much non-clonal antibody (bovine IgG) is present in our preparations.  
  
3.2. Commercial anti-bovine IgG reagents cross-react with mouse IgGs. 
 
In order to specifically detect the presence of bovine IgG in bioreactor produced mouse 
mAbs, we ran sandwich ELISA experiments first, where commercially available polyclonal 
antibodies were used. The sandwich ELISA was sensitive (approx 3 ng/ml) and recognized 
bovine IgG (purified IgG or serum IgG) dose-dependently (Figure 2 panel A).  In addition, the 
results indicated that our bioreactor produced monoclonal mAb preparations contain bovine 
immunoglobulin (Figure 2 panel A). However, when we extended the analysis and used 
mouse ascites (in vivo) produced mAbs or mouse sera derived pure mouse IgG, these were all 
positive in the sandwich ELISA (ELISA 2.), indicating that our assay, that is supposedly 
bovine IgG specific, in fact, cross reacts with mouse IgG (Figure 2 panel C). We have tested 
another set of antibodies from a different vendor and the components of the sandwich ELISA-
s were exchanged between the two vendors’ products, but neither these actions nor 
optimization procedures including concentration titration of components resulted in more 
specific results (results not shown). Western blot analysis showed that indeed the commercial 
antibodies declared to be bovine Ig specific recognize both bovine and murine IgG (Figure 2 
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panel C). On the contrary, the reagents declared to be mouse Ig specific (ELISA 3.), clearly 
do not cross react with bovine IgG (Figure 2 panel D).  
 
3.3. Production and characterization of anti-bovine-IgG, species specific monoclonal 
antibodies 
 
Monoclonal antibodies were generated against bovine IgG. Eight hybridomas were selected 
for cloning via limiting dilution, resulting in thirty-five IgG producing monoclonal 
hybridomas of which eight (one from each hybridomas) were further characterized in direct, 
sandwich, and competitive ELISA-s. Based on isotype ELISA tests (not shown), all the eight 
monoclonal hybridomas produced IgG1 isotype. Five of the eight hybridomas produced anti-
bovine IgG with high affinity (Bsi4028, Bsi4032, Bsi4033, Bsi4034, Bsi4035), giving 
appreciable signal already at 100 ng/ml bovine IgG coating concentration (ELISA 4.), while 
the remaining three (Bsi4029, Bsi4030, Bsi4031) showed reduced relative affinities providing 
relatively low signal even at 1 µg/ml bovine IgG concentration used for coating (Figure 3 
panel A). Subsequently, the five better performing mAbs were further characterized with 
sandwich ELISA in combinations. In these experiments all five mAbs were used as capture 
mAbs, reacted with a series of concentrations of purified bovine IgG; the captured antigen 
was then detected with all five biotinylated mAbs via streptavidin-HRP complexes in separate 
experiments, in a total of twenty-five different combinations (ELISA 5.). The sandwich 
ELISAs demonstrated that each of the mAb couples produces very similar results and shows 
comparable characteristics. The results are illustrated with one representative data set, where 
biotinylated Bsi4035 was used as the detection antibody (Figure 3 panel B). In all cases 10 
ng/ml bovine-IgG produced reproducible high signal, the limit of detection was ≥ 1 ng/ml, 
from which point specific signals were significantly higher (p<0.05) than the background 
signals. 
In order to be able to find optimal pairs for sandwich ELISA-s, we further characterized the 
five selected mAbs in an inhibition test to query whether the relative affinities differed 
significantly from each other. In these experiments, fixed amount of biotinylated monoclonal 
antibodies were mixed with a series of different concentrations of all the five bovine IgG 
specific unlabeled antibodies individually and were added to the wells of the ELISA plates 
containing fixed amount of the antigen, bovine-IgG. ELISA-s were developed with HRP-
Streptavidine as usual (ELISA 6.). The IC50s (50% inhibitory doses) were calculated and 
were normalized to the “self” sandwich, which was the setup where the biotinylated mAb was 
the same as the unlabeled inhibitor. Important to note here, that because of the dimeric 
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structure of IgG sandwich ELISAs can be built with a single epitope specific mAb. Using the 
table (Figure 3 panel D) we attempted to rank the mAbs, however we noted only negligible 
differences, thus we concluded that any of the mAbs (Bsi4028, Bsi4032, Bsi4033, Bsi4034, 
Bsi4035) would be fit for the development of a species specific sandwich ELISA alone or in 
combination with any other.  
Finally, in order to test species specificity, from lower vertebrate to hominid and human, we 
performed immunoblotting and sandwich ELISA experiments where for the western blotting 
sera from a wide variety of vertebrate species were separated by SDS-PAGE under reducing 
conditions, and after blotting, were probed with a polyclonal antibody declared to be bovine 
IgG specific (Figure 4 panel A) and with Bsi4028 (Figure 4 panel C) or Bsi4032 (not shown). 
Sandwich ELISA results obtained with polyclonal antiserum declared to be bovine specific is 
shown on Figure 4, panel B, while reactivity of Bsi4028 (results obtained with Bsi4032 are 
not shown) is presented on Figure 4 panel D. Overall, the results indicate, that mAb Bsi4028 
and Bsi4032 react with a limited species-specific (species specificity with limited cross-
species recognition) epitope (both native and denatured), present on the heavy chain of the 
ruminant mammal species (bovine, goat and sheep) and possibly in a related but evolutionary 
more distant and therefore weaker version in lion, tiger, simian monkey, gorilla and human. In 
addition to the IgG heavy chain reactivity of bovine IgG, a weak reaction of the bovine light 
chain is also observed. This reactivity may be due to the presence of a related weakly reactive 
epitope on the bovine light chain. Most importantly, the mAb Bsi4028 does not react with 
rodent IgG and IgG from lower vertebrate like swan, eagle, turkey, chicken, painted turtle, 
moorish tortoise. While the rabbit anti-bovine IgG polyclonal antibody detects epitopes 
present on both light and heavy chains of bovine IgG and all other species from rodents up to 
a hominid (gorilla) and human. Species from reptiles to birds, at lover level of the 
phylogenetic tree fail to react with the polyclonal sera. The reaction pattern indicates that 
Bsi4028 and Bsi4032 react in a limited species-specific manner. Results shown on Figure 3 
panel C strongly suggest that each of the mAb-s (Bsi4028, Bsi4032, Bsi4033, Bsi4034, 
Bsi4035) react with the same epitope of bovine IgG. As Bsi4028 and Bsi4032 provided 
identical results in these experiments taken together with the results in western blot 
experiments we suggest that mAbs Bsi4028, Bsi4032, Bsi4033, Bsi4034, Bsi4035, all possess 
identical limited species specificity. Further, sandwich ELISA experiments indicate that 
limited species specificity at least for BSI4028 and BSI4032 are valid with respect to natural 
(see ELISA results) and denatured (SDS-PAGE, denaturing conditions in western blot 
experiments) epitopes (Figure 4).  
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3.4. Sandwich ELISA development for the detection of bovine IgG contamination. 
In order to generate a quantitative assay to determine bovine IgG contamination in bioreactor 
produced mouse mAb, we developed a sandwich ELISA, using Bsi4028 mAb as capture and 
the Bsi4032-biot as detection mAbs (ELISA 6.) to test whether the low 10 ng/ml 
concentration of bovine IgG would be detectable in the presence of excess mouse IgG. As 
shown on Figure 5 A, 10 ng bovine IgG can be adequately quantified even in the presence of 
a wide range, (from 5 ng/ml to 0.5 mg/ml, up to 5x10
4
-fold excess) of mouse IgG. Figure 5 B 
shows that the sandwich ELISA between the Bsi4028 capture and the Bsi4032-biot detection 
mAbs detects bovine IgG contamination in an in vitro produced mouse mAb preparation. 
Finally, we used this sandwich ELISA to quantify the bovine IgG contamination of different 
monoclonal antibody preparations in parallel with two other sandwich ELISA-s, which we 
constructed using commercially available antibodies declared to be bovine IgG specific. The 
samples were diluted to set the mAb concentrations of the preparations between 21 and 35 
µg/ml, and their bovine IgG content was determined. The antibody pair Bsi4028 and Bsi4032-
biotin bovine IgG specific mAb pairs did not detect any bovine IgG in preparations derived 
from mouse ascites, while both ELISA-s constructed from commercial antibodies reported the 
presence of variable amount of bovine IgG. Bovine IgG contamination was detectable in the 
in vitro generated mAb preparations with all three sandwich ELISA pairs (Table 1.), but the 
detected amount of bovine IgG was considerable lower in case of the Bsi4028 and Bsi4032-
biotin pair. While with the Bsi4028 and Bsi4032-biotin based sandwich ELISA we detected 
between 0.3 and 8.3 % as “contamination”, the two commercial preparations detected 
between 7.1 and 32.7 % or between 32.5 and 69.2 % bovine IgG contamination respectively. 
For monoclonal antibody production in bioreactor systems (in vitro), the use of serum-free 
media are recommended, however, for various reasons a significant amount of mAbs are 
produced in culture media containing bovine protein supplement. The use of bovine serum in 
hybridoma culture medium will introduce bovine immunoglobulins to the culture fluids which 
may considerably influence the further application of antibodies produced in bovine serum 
supplemented media (Darby et al. 1993). As a solution, specifically defined serum-free media 
have been formulated to support hybridoma growth (Tarleton and Beyer 1991; Federspiel et 
al. 1991). However, several authors reported the decline and loss of mAb productivity during 
long-term culture of hybridomas adapted to serum-free media (Frame and Hu, 1990; Ozturc 
and Palsson, 1990). Moreover, Rasmussen et al. reported that media defined as serum-free 
may contain even 0.5 mg/l bovine IgG (Rasmussen et al., 2005). These alarming observations 
indicate that mAbs produced even in serum-free defined media may contain bovine IgG 
impurities. Thus, there is a definitive need to precisely determine bovine IgG contamination is 
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mAb preparations. To detect and quantify the presence of bovine IgG in mAbs preparations 
produced in bioreactors where bovine serum supplemented culture medium is used, we 
attempted to measure bovine IgG content with commercial anti-bovine antibodies, however, 
our results were inconsistent. Here we show that the commercially available anti-bovine 
antibodies cross react with mouse IgG and therefore falsely “recognize” mouse IgGs not only 
if produced in bioreactor but also in IgG preparations derived from mouse ascites which does 
not contain bovine proteins at all. Our data show that cross-reactivity of commercially 
available anti bovine Ig inhibits or at least severely limits their use for analytical quantitation 
of bovine IgG contamination. The apparently limited species specific anti-bovine IgG reacting 
mAbs (Bsi4028, Bsi4032, Bsi4033, Bsi4034, Bsi4035) reported here, did not show any 
detectable cross-reactivity with mouse IgGs, neither in ELISA nor in Western-blot 
applications. These results qualify Bsi4028, Bsi4032, Bsi4033, Bsi4034, Bsi4035 mAbs for 
analytical quantitation of bovine IgG contamination in in vitro produced mouse mAbs and 
mouse IgG Fc-containing fusion proteins as shown by our western blot and sandwich ELISA 
assays. 
 
3.5. Removal of bovine-IgG from mixes that contain mouse IgG.  
In order to validate the apparently bovine IgG specific mAbs for the use of specific removal 
of bovine IgG from biological mixes that contain excess amount of mouse IgG, first we tested 
artificial mixes. We show that from mixes containing 10% and 20% excess of bovine IgG as 
compared to mouse IgG, we were able to remove most of the bovine IgG as after removal we 
observed either no detectable bovine IgG or ≤ 0.03%. (Table 2.).  Moreover, we show that a 
bioreactor derived mouse mAb preparation can also be efficiently depleted of bovine IgG 
(Table 2.).  
 
Conclusion. 
Our results indicate the existence of a sufficiently antigenic IgG epitope of bovine IgG, which 
allows generation of mABs with (limited) species-specificity. The limited species-specific 
mAbs are readily applicable for sensitive detection of bovine IgG in the presence of excess 
amount of mouse IgG, moreover the mAbs are useful for specific removal of bovine IgG from 
mixes that contain excess amount of mouse IgG.   
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Figure legends: 
 
Fig. 1. Purity control of monoclonal antibodies. In vitro (upper panels; using bioreactors), 
or in vivo (lower panels; mouse ascites) produced monoclonal antibodies (Bsi0452-4 and 
Bsi0452-5 respectively) were subjected to Multi Capillary Gel Electrophoresis (mCGE) (A 
and D); SDS-PAGE (B and E) or Isoelectric focusing (IEF-PAGE) (C and F).  
 
Fig. 2. Reactivity of commercially available anti bovine IgG and anti-mouse IgG specific 
reagents with different mouse and bovine IgG preparations. Sandwich ELISAs for 
quantitative determination of bovine (A) or mouse IgG-s (B) were set using commercially 
available reagents as described in materials and methods (ELISA 2.; ELISA 3.). Serial 
dilutions of serum purified mouse and bovine polyclonal IgG-s and mouse monoclonal 
antibodies produced eiter in vitro in bioreactors or in vivo in mice were tested in the ELISA-s. 
Murine and Bovine IgGs isolated from sera of the animals were separated at various amounts 
-PAGE, were blotted to NC membrane and detected with anti-bovine 
IgG HRP (C), or with goat anti-mouse IgG HRP (D).   
 
Fig. 3. Portrayal of selected anti-bovine monoclonal antibodies. Eight anti-bovine IgG 
mAbs were first analyzed with direct ELISA (ELISA 4.) using bovine IgG as immobilized 
antigen (A). Five mAbs showing higher relative affinity to bovine IgG were further 
characterized using a sandwich ELISA (ELISA 5. see materials and methods) in all possible 
combinations. The results are illustrated with one representative data set, where biotinylated 
Bsi4035 mAb was used as the detection antibody (B). To further  analyse the antibodies an 
inhibiton ELISA was set (ELISA 6. see materials and methods)  and used to examine possible 
interactions between the mAb-s (C). Results with one representative antibody (Bsi4035) is 
plotted (C). 50% inhibitory doses were calculated and were normalized to the “self” 
sandwich, which was the setup where the biotinylated mAb was the same as the unlabeled 
inhibitor (D).  
 
Fig. 4. Immunoblot analysis of species specificity of anti-bovine antibodies. Sera samples 
from different species [human (Homo sapiens sapiens), gorilla (Gorilla gorilla), Simian 
(Erythrocebus patas), tiger (Panthera tigris), lion (Panthera leo), dog (Canis familiaris), 
horse (Equus caballus), camel (Camelus bactrianus), alpaca (Vicugna pacos), pig (Sus scrofa 
domestica), goat (Capra aegagrus hircus), sheep (Ovis aries aries), rabbit (Oryctolagus 
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cuniculus domestica), BALB/c mouse (Mus musculus), SCID mouse (Mus musculus, 
scid/scid), rat (Rattus rattus), crow (Corvus cornix), swan (Cygnus olor), eagle (Aquila 
heliaca), turkey (Meleagris gallopavo domesticus), chicken (Gallus gallus domesticus), 
painted turtle (Trachemys scripta), Moorish tortoise (Testudo graeca) were separated using 
reducing SDS-PAGE and after immobilization were probed with a commercial anti-bovine 
IgG (Panel A) and, Bsi4028 mAb (Panel C). Sera from different species (as on panels A and 
B) were tested in sandwich ELISA experiments using commercial anti-bovine IgG (Panel B) 
and, Bsi4028 mAb (Panel C) as detection reagents (ELISA 2 and ELISA 7, respectively in 
Materials and Methods section).  
 
 Fig. 5. Demonstration of specific recognition of bovine IgG of anti bovine mAb-s in the 
presence of varying amount of murine IgG.  Cross reactivity with bovine IgG was tested in 
a sandwich ELISA (ELISA 7. Bsi4028 and Bsi4032-Biot) using fixed, low amount of bovine 
IgG (10 ng/ml) in the presence of varying amount (covering 6 order of magnitude) of murine 
IgG (panel A). Measurement of bovine IgG content of different IgG preparations using the 
sandwich ELISA (panel B). 
 
Table 1. Determination of bovine IgG contamination of different monoclonal antibody 
preparations (in vivo and in vitro produced mAb) Bovine IgG content was determined 
using a sandwich assay derived from BSI’s monoclonal antibodies in parallel with two 
sandwich ELISA-s constructed from commercial reagents declared to be bovine IgG specific. 
 
Table 2. Removal of bovine-IgG from mixes that contain mouse IgG. The efficiency of 
depletion of bovine IgG contamination via the bovine IgG removal column was tested using 
the mixture of mouse and bovine IgG (Experiment 1 and 3) 10% and 20% respectively, or in 
vivo produced Bsi mAb (Bsi0452) with added bovine IgG contamination (Experiment 4) or in 
vitro produced Bsi mAb Bsi1328, (Experiment 2). Bovine IgG was quantified via sandwich 
ELISA between the Bsi4028 capture and the Bsi4032-Biot. No bovine IgG contamination was 
detected in Experiment 2-4, while the vast majority of the bovine IgG was removed with a 
single column chromatography step resulting in merely traces amount (≤0.03%) of bovine 
IgG in experiment 1. 
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